Acute pancreatitis cost-effectiveness of therapy
|
Acute pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute pancreatitis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute pancreatitis cost-effectiveness of therapy |
|
Acute pancreatitis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Acute pancreatitis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]
Cost-Effectiveness of Therapy
Economic analyses of acute pancreatitis management consistently demonstrate that guideline-concordant strategies — same-admission cholecystectomy, endoscopic step-up approaches, moderate fluid resuscitation, and early enteral nutrition — reduce both direct costs and long-term morbidity compared with delayed or more invasive alternatives.
Economic Burden of Acute Pancreatitis
Acute pancreatitis generates approximately 300,000 hospitalizations annually in the United States at a cost exceeding $2.6 billion per year.[1][2]
A 2025 US claims analysis found mean acute-pancreatitis-related expenditures of $31,119 per short-term episode and $12,470 during one-year follow-up, totaling approximately $43,600 per patient.[3]
Costs increase substantially with disease severity — ICU-level severe disease carries significantly higher index and post-discharge costs than non-ICU hospitalizations.[4] Gallstone-induced acute pancreatitis generates higher hospitalization charges than alcohol-induced disease ($61,182 vs $37,982), attributed to greater imaging and procedural utilization.[2]
Same-Admission Cholecystectomy: Cost Savings Through Recurrence Prevention
Same-admission cholecystectomy for mild gallstone pancreatitis is both clinically superior and more cost-effective than interval cholecystectomy.[1][2]
Without cholecystectomy, 18% of patients are readmitted for recurrent biliary events (including 8% with recurrent pancreatitis), generating avoidable costs from emergency visits, readmissions, repeat imaging, and ERCP.[1]
The PONCHO trial demonstrated that same-admission cholecystectomy reduced gallstone-related readmission from 17% to 5% (RR 0.28) without increasing operative complications.[5]
A 2026 Swedish nationwide study (n=9,593) confirmed that no-intervention strategies had the highest recurrence (17.5%) and complication rates, while same-admission cholecystectomy had the lowest (3.4% recurrence, 1.6% other complications).[6]
Despite this, fewer than half of eligible patients undergo same-admission cholecystectomy in practice, representing a significant missed opportunity for cost savings.[1]
Step-Up Approach Versus Open Necrosectomy: Reduced Costs and Morbidity
The PANTER trial demonstrated that the minimally invasive step-up approach reduced total costs compared with open necrosectomy, in addition to reducing complications and long-term pancreatic insufficiency.[7]
Specifically, new-onset diabetes (16% vs 38%), pancreatic enzyme use (7% vs 33%), and incisional hernias (7% vs 24%) were all lower — each representing ongoing downstream healthcare costs avoided.[7]
Long-term follow-up confirmed sustained superiority without increased reintervention rates.[7]
A US national database analysis (2016–2019; n=4,605) found that open approaches were associated with $58,700 higher costs and 12 additional hospital days compared with minimally invasive debridement.[8]
Endoscopic Versus Surgical Step-Up: Cost-Effectiveness Data
The MISER trial provided the most direct cost comparison: total direct and indirect costs were $75,830 per patient for the endoscopic approach versus $117,492 for minimally invasive surgery — a savings of $41,662 per patient. The probability of the endoscopic approach being cost-effective was 86% at a $50,000/QALY willingness-to-pay threshold.[9]
The TENSION trial showed a non-significant trend toward lower costs with the endoscopic approach (€60,228 vs €73,883; mean difference −€13,655), with an 89.6% probability of cost-effectiveness at €50,000/QALY.[10]
A 2022 decision-model analysis using Medicare reimbursement rates confirmed the endoscopic step-up as the dominant economic strategy (7.92 QALYs for $90,864 vs 7.83 QALYs/$100,932 for surgical step-up vs 7.52 QALYs/$109,272 for open necrosectomy).[11]
A 2025 network meta-analysis of 21 studies (1,850 patients) confirmed that endoscopic approaches had the lowest cost ($95,156), highest effectiveness, and 97.2% probability of cost-effectiveness at a $100,000/QALY threshold.[12]
| Strategy | Approximate Cost per Patient | Key Economic Finding |
|---|---|---|
| Endoscopic step-up | $75,830 – $95,156 | Dominant / highest probability of cost-effectiveness (86–97%) |
| Surgical step-up | $100,932 – $117,492 | Higher cost, comparable or inferior outcomes |
| Open necrosectomy | $109,272+ | Highest cost and morbidity |
Enteral Nutrition Versus TPN: Cost and Outcomes Advantage
Enteral nutrition is strongly preferred over total parenteral nutrition (TPN) on both clinical and economic grounds. TPN carries costs of central line placement and maintenance, catheter-related sepsis, electrolyte monitoring, and metabolic complications — all avoidable with enteral feeding.[2]
Multiple meta-analyses demonstrate that enteral nutrition reduces mortality (RR 0.50), organ failure (RR 0.55), and systemic infection (RR 0.39) compared with TPN.[13]
Standard polymeric formulations are preferred over costlier semi-elemental formulations, which show no clinical advantage.[2]
Moderate Versus Aggressive Fluid Resuscitation: Avoidable Harm
The WATERFALL trial demonstrated that aggressive fluid resuscitation increased fluid overload (20.5% vs 6.3%) without improving outcomes, with a trend toward longer hospitalization (median 6 vs 5 days).[14]
Avoiding aggressive protocols reduces fluid-related complications (pulmonary edema, abdominal compartment syndrome) and their associated ICU utilization and costs.[15]
LAMS Versus Plastic Stents: Equivalent Outcomes, Different Costs
A 2025 meta-analysis of 8 RCTs (>500 patients) found no difference in clinical success, adverse events, mortality, or need for necrosectomy between metal and plastic stents for walled-off necrosis drainage.[16]
Metal stents shortened procedure duration but cost significantly more per device. Given equivalent clinical outcomes, stent selection should be guided by institutional expertise and cost considerations.
Postponed Versus Immediate Intervention: Cost Implications of the POINTER Trial
The POINTER trial showed that postponed drainage required fewer total interventions (mean 2.6 vs 4.4) than immediate drainage, with 39% of postponed patients avoiding drainage entirely through antibiotics alone.[17]
Each avoided procedure represents savings in operative costs, ICU time, and complication management.
Procalcitonin-Guided Antibiotic Stewardship
The PROCAP trial demonstrated that procalcitonin-guided algorithms reduced antibiotic prescriptions (45% vs 63%) and antibiotic days without increasing infections or mortality.[2]
Reduced antibiotic utilization translates to direct drug cost savings and potentially lower rates of antimicrobial resistance-related complications.
Clinically Actionable Cost-Effectiveness Recommendations
- Perform same-admission cholecystectomy for mild gallstone pancreatitis — it is both clinically superior and cost-saving compared with delayed surgery.[1][5]
- Use the endoscopic step-up approach as first-line for infected necrotizing pancreatitis when anatomically feasible — it is the most cost-effective strategy with 86–97% probability of cost-effectiveness.[9][10]
- Delay intervention ≥4 weeks in stable patients — postponement reduces the total number of procedures and allows >1/3 of patients to avoid drainage entirely.[17]
- Use enteral nutrition over TPN — lower cost, fewer complications, and superior outcomes.[13][2]
- Use moderate rather than aggressive fluid resuscitation — aggressive protocols increase complications without clinical benefit, generating avoidable costs.[14]
- Choose plastic or metal stents based on local expertise and cost — clinical outcomes are equivalent.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Tenner S, Vege SS, Sheth SG; et al. (2024). "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis". Am J Gastroenterol. 119 (3): 419–437. doi:10.14309/ajg.0000000000002645.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE (2024). "Diagnosis and Management of Acute Pancreatitis". Gastroenterology. 167 (4): 673–688. doi:10.1053/j.gastro.2024.02.052.
- ↑ Sikora Kessler A, Soffer DE, Abramovitz L; et al. (2025). "Episodic and Long-Term Costs of Acute Pancreatitis Requiring Hospitalization Among Adults in US Clinical Practice". Pancreas. 54 (5): e481–e488. doi:10.1097/MPA.0000000000002599.
- ↑ Pokras S, Ray M, Zheng S, Ding Y, Chen CC (2021). "The Short- And Long-Term Burden of Acute Pancreatitis in the United States: A Retrospective Cohort Study". Pancreas. 50 (3): 330–340. doi:10.1097/MPA.0000000000001757.
- ↑ 5.0 5.1 da Costa DW, Bouwense SA, Schepers NJ; et al. (2015). "Same-Admission Versus Interval Cholecystectomy for Mild Gallstone Pancreatitis (PONCHO): A Multicentre Randomised Controlled Trial". Lancet. 386 (10000): 1261–1268. doi:10.1016/S0140-6736(15)00274-3. PMID 26460661.
- ↑ Selin D, Oskarsson V, Maret-Ouda J; et al. (2026). "Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis". JAMA Surg. doi:10.1001/jamasurg.2026.2168.
- ↑ 7.0 7.1 7.2 Hollemans RA, Bakker OJ, Boermeester MA; et al. (2019). "Superiority of Step-Up Approach vs Open Necrosectomy in Long-Term Follow-Up of Patients With Necrotizing Pancreatitis". Gastroenterology. 156 (4): 1016–1026. doi:10.1053/j.gastro.2018.10.045.
- ↑ Tran Z, Xu J, Verma A; et al. (2023). "National Trends and Clinical Outcomes of Interventional Approaches Following Admission for Infected Necrotizing Pancreatitis in the United States". J Trauma Acute Care Surg. 94 (5): 665–671. doi:10.1097/TA.0000000000003934.
- ↑ 9.0 9.1 Bang JY, Arnoletti JP, Holt BA; et al. (2019). "An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis". Gastroenterology. 156 (4): 1027–1040.e3. doi:10.1053/j.gastro.2018.11.031.
- ↑ 10.0 10.1 Onnekink AM, Boxhoorn L, van Dijk SM; et al. (2023). "Cost-Effectiveness of the Endoscopic Versus Surgical Step-Up Approach for Infected Necrotizing Pancreatitis in the TENSION Trial". Br J Surg. 110 (4): 426–434. doi:10.1093/bjs/znac438.
- ↑ Prasath V, Quinn PL, Oliver JB; et al. (2022). "Cost-Effectiveness Analysis of Infected Necrotizing Pancreatitis Management in an Academic Setting". Pancreatology. 22 (2): 185–193. doi:10.1016/j.pan.2021.11.011.
- ↑ Tan HL, Zhao Y, Chua DW; et al. (2025). "Comparison of Treatment Approaches for Infected Necrotizing Pancreatitis: A Systematic Review and Network Meta-Analysis". J Gastrointest Surg. doi:10.1016/j.gassur.2025.102152.
- ↑ 13.0 13.1 Mederos MA, Reber HA, Girgis MD (2021). "Acute Pancreatitis: A Review". JAMA. 325 (4): 382–390. doi:10.1001/jama.2020.20317.
- ↑ 14.0 14.1 de-Madaria E, Buxbaum JL, Maisonneuve P; et al. (2022). "Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis". N Engl J Med. 387 (11): 989–1000. doi:10.1056/NEJMoa2202884.
- ↑ McDermott J, Kao LS, Keeley JA, Nahmias J, de Virgilio C (2024). "Management of Gallstone Pancreatitis: A Review". JAMA Surg. doi:10.1001/jamasurg.2024.2580.
- ↑ Holanda EU, Fondelli AA, de Freitas Kleimmann R; et al. (2025). "Metal Stents Versus Plastic Stents for Drainage of Pancreatic Fluid Collections: A Systematic Review and Meta-Analysis of Randomized Trials With Trial Sequential Analysis". Surg Endosc. 39 (3): 1449–1461. doi:10.1007/s00464-024-11522-2.
- ↑ 17.0 17.1 Boxhoorn L, van Dijk SM, van Grinsven J; et al. (2021). "Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis". N Engl J Med. 385: 1372–1381. doi:10.1056/NEJMoa2100826.